Physician profile
Austin Hwang
NPI 1457569691
$9,038.93
in general payments reported to CMS, 2019-2025
37 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $519 · 2021: $786 · 2022: $1,246 · 2023: $1,932 · 2024: $2,064 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,656.30 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,069.30 | 2019-2025 | |
| Janssen Biotech, INC. | $1,063.87 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $930.30 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $790.14 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $648.99 | 2021-2024 | Zeposia |
| Pfizer INC. | $297.47 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $286.50 | 2020-2025 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $260.42 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $224.52 | 2019-2025 | |
| Lilly USA, LLC | $219.93 | 2024-2025 | Omvoh |
| Genzyme Corporation | $203.50 | 2022-2025 | |
| Amgen INC. | $195.69 | 2019-2025 | Avsola, Amjevita, Uplizna |
| Ardelyx, INC. | $184.41 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $183.88 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $182.05 | 2022-2025 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $157.09 | 2019-2024 | Ocaliva |
| Qol Medical, LLC | $156.45 | 2019-2024 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $153.89 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $99.43 | 2025 | Rezdiffra |
| Cook Medical LLC | $97.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $95.74 | 2023 | Zeposia |
| Redhill Biopharma INC. | $79.21 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $71.04 | 2021-2023 | |
| Alfasigma USA, INC. | $63.62 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $41.89 | 2025 | Zenpep |
| Therapeuticsmd, INC. | $39.41 | 2019 | |
| Fresenius Kabi USA, LLC | $36.02 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $29.93 | 2022 | |
| Organon LLC | $24.80 | 2023 | Renflexis, Hadlima |
| Intra-Sana Laboratories | $22.57 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Digestive Care, INC. | $20.16 | 2025 | Pertzye |
| Celltrion USA INC. | $19.81 | 2024 | Zymfentra |
| Astrazeneca Pharmaceuticals LP | $19.59 | 2023 | Andexxa |
| Novo Nordisk INC | $19.03 | 2019 | |
| Sandoz INC. | $18.63 | 2024 | Hyrimoz |
| Phathom Pharmaceuticals, INC. | $18.49 | 2025 | Voquezna |
| Amarin Pharma, INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.